Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Genital Warts Market – Industry Trends and Forecast to 2028

Pharmaceutical | Published Report | Aug 2021 | MEA | 350 Pages | No of Tables: 139 | No of Figures: 53

Report Description

Middle East and Africa Genital Warts Market, By Morphology (Cauliflower-Like, Smooth Papular, Keratotic, and Flat Warts), Type (Prevention, Diagnostics, Treatment), Cause (HPV 6, HPV 11, Others), Location (Vulva, Cervix Uteri, Urethra, Anus, Scrotum), Gender (Male and Female), Dosage (Cream, Gel, Ointment, Intramuscularly and Others), End-User (Hospitals, Diagnostic Centers, Surgical Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Pharmacy Stores and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel and rest of the Middle East and Africa) Market Trends and Forecast to 2028.  

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Middle East and Africa Genital Warts Market

Middle East and Africa genital warts market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.7% in the forecast period of 2021 to 2028 and is expected to reach USD 320.38 million by 2028 from USD 228.90 million in 2020. The rising incidence of STDs and the growth of novel technological advancements for genital warts are likely to be the major drivers which propel the demand of the market in the forecast period.

Genital warts are one of the most recurrent types of sexually transmitted infections. The human papillomavirus is the virus responsible for causing genital warts. People will get infected with at least one type of human papillomavirus (HPV) at some point during their lives. Genital warts affect most of the moist tissues in the genital areas of male and female patients. Although the genital infection is asymptomatic, it's frequently recognized as genital warts due to the onset of symptoms. It is estimated that around 1% of sexually active men and women in the United States have genital warts.

Genital warts are caused due to the human papillomavirus (HPV). There are around 30-40 strains of HPV. However, only a few of the strains cause genital warts. The virus is easily transmittable through skin-to-skin contact. Hence it's considered a sexually transmitted infection (STI). The Center for Disease Control and Prevention (CDC) says that people get genital warts due to the mutant activity of HPV.

Various factors suchs as lack of sanitation and hygiene in developing countries of the Middle East, surge in prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections, rise in patients, rise in government initiatives and awareness programs, and use of cryotherapy for genital warts treatment is expected to drive the Middle East and Africa genital warts market. However, the side effects noticed while undergoing treatment for genital warts and lack of patient and consumer awareness, and lack of funds for the development of diagnostic centers are the restraints that are expected to hinder the genital warts market growth.

Moreover, the rise in clinical trials, rise in healthcare expenditure and strategic initiatives by market players, and huge market potential in developing countries bolsters the genital warts market growth.  On the other hand, the rise in product recalls associated with vaccines, and topical administration of genital warts, and patient compliance regarding the use of vaccines are the restraints that can hinder the market growth.

The Middle East and Africa genital warts market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Get Exclusive Sample Copy of this Report Here

Middle East and Africa Genital Warts Market Scope and Market Size

The Middle East and Africa genital warts market is segmented on the basis of morphology, type, cause, location, gender, dosage, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of morphology, the Middle East and Africa genital warts market is segmented into flat warts, smooth papular, cauliflower-like, and keratotic. In 2021, the cauliflower-like segment is expected to dominate the Middle East and Africa genital warts market due to the rise in cases of genital warts due to the cauliflower morphology.
  • On the basis of type, the Middle East and Africa genital warts market is segmented into prevention, diagnostics and In 2021, the prevention segment is expected to dominate the Middle East and Africa genital warts market due to the rise in awareness programs for prevention and treatment of genital warts in male and female patients, via seminars and conferences.
  • On the basis of cause, the Middle East and Africa genital warts market is segmented into HPV 6, HPV 11, and others. In 2021, the HPV 6 segment is expected to dominate the Middle East and Africa genital warts market, owing to the HPV 6 strain causing 90%  of genital warts in female patients in Africa
  • On the basis of location, the Middle East and Africa genital warts market is segmented into cervix uteri, urethra, anus, vulva, and scrotum. In 2021, the vulva segment is expected to dominate the Middle East and Africa genital warts market because the prevalence rate in women is higher than in men.
  • On the basis of gender, the Middle East and Africa genital warts market is segmented into male and female. In 2021, the female segment is expected to dominate the Middle East and Africa genital warts market due to the females aged 21-29 years suffering from genital warts and low immunity in women.
  • On the basis of dosage, the Middle East and Africa genital warts market is further sub-segmented into cream, gel, ointment, intramuscularly, and others. In 2021, the cream segment is expected to dominate the Middle East and Africa genital warts market due to increased acceptance of Condylox by the patients of the Middle East and Africa.
  • On the basis of end-users, the Middle East and Africa genital warts market is segmented into hospitals, diagnostic centers, surgical centers, ambulatory surgical centers, and others. In 2021, the hospital's segment is expected to dominate the Middle East and Africa genital warts market as hospitals patients have all the facilities as they can directly contact doctors and dermatologists who can diagnose the disease and cure the warts disease and presence of healthcare reimbursement.
  • On the basis of distribution channels, the Middle East and Africa genital warts market is segmented into direct tender, pharmacy stores, and others. In 2021, the direct tender segment is expected to dominate the Middle East and Africa genital warts market as there is no requirement of the prescription of doctors and a rise in a number of customers and contracts with healthcare organizations and wholesalers.

Middle East and Africa Genital Warts Market Country Level Analysis

The Middle-East and Africa genital warts  market is analyzed, and market size information is provided by product and services, sample type, process, application, compound library size, end-user, and distribution channel

The countries covered in the Middle-East and Africa genital warts market report are South Africa, Saudi Arabia, UAE, Egypt, Israel, and the Rest of the Middle East and Africa.

The Middle East and Africa are expected to grow with a substantial growth rate in the forecast period of 2020 to 2028 as Middle East and Africa counties are major developing countries and focus on increasing R&D activities in the pharma and biotech sector and increase outsourcing services. South Africa is expected to dominate in the market in the Middle East and Africa market.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

The Growth Potential For The Genital Warts In Emerging Economies And The Strategic Initiatives By Market Players Are Creating New Opportunities In The Middle East And Africa Genital Wartsmarket.

 The Middle East and Africa genital warts market also provide you with detailed market analysis for every country's growth in a particular industry with the genital warts treatment products sales, impact of advancement in genital warts, and changes in regulatory scenarios with their support for the Middle East and Africa genital warts market. The data is available for the historic period 2010 to 2019.

Competitive Landscape and the Middle East and Africa Genital wartsMarket Share Analysis

Middle East and Africa genital warts market competitive landscape provide details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the Middle East and Africa genital warts market.

The major companies providing the Middle East and Africa genital warts are Bausch Health Companies Inc., Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc, Taro Pharmaceutical Industries Ltd, Glenmark Pharmaceutical Inc., USA (a subsidiary of Glenmark Pharmaceuticals Ltd.), GlaxoSmithKline plc, Fotona, Orgenesis Inc, Perrigo Company plc among others.

The strategic initiatives by market players, along with new technological advancements for genital warts, is bridging the gap for chronic wounds treatment. 

For instance,

  • In June 2021, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., had declared the U.S. FDA approval for GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of HPV-related cervical, vaginal, vulvar, anal, oropharyngeal, and other head and neck cancers. The FDA approval received would result in addressing the unmet clinical needs for the patients, increased distribution of the vaccine in hospitals and cancer research institutes for the rise in product sales

Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the Middle East and Africa genital warts market, which also provides the benefit for an organization to improve their offering for treatment products.


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA GENITAL WARTS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 DISTRIBUTION CHANNEL LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

5 EPIDEMIOLOGY

6 PORTER'S FIVE FORCES MODEL

7 PESTEL ANALYSIS

8 PIPELINE ANALYSIS: MIDDLE EAST AND AFRICA GENITAL WARTS MARKET

9 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: REGULATIONS

9.1 CANADA

9.2 U.S.

9.3 EUROPE

9.4 JAPAN

9.5 MALAYSIA

9.6 VIETNAM

9.7 SOUTH AMERICA

10 MARKET OVERVIEW

10.1 DRIVERS

10.1.1 RISE IN PREVALENCE OF SEXUALLY TRANSMITTED DISEASES AND HUMAN PAPILLOMAVIRUS (HPV) VIRUS

10.1.2 RISE OF MALE POPULATION

10.1.3 RISE IN GOVERNMENT INITIATIVES AND AWARENESS PROGRAMMES

10.1.4 RISE IN CLINICAL TRIALS

10.1.5 RISE IN HEALTHCARE EXPENDITURE

10.2 RESTRAINTS

10.2.1 RISE IN COST FOR GENITAL WARTS TREATMENT

10.2.2 SIDE EFFECTS OBSERVED WHILE UNDERGOING THE TREATMENT FOR GENITAL WARTS

10.2.3 LACK OF PATIENT AND CONSUMER AWARENESS

10.2.4 LESS DIAGNOSTIC RATE

10.3 OPPORTUNITIES

10.3.1 USE OF LASER TREATMENT AND CRYOTHERAPY FOR TREATMENT OF GENITAL WARTS.

10.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS.

10.3.3 RESEARCH AND DEVELOPMENT FOR GENERIC MEDICATIONS

10.4 CHALLENGES

10.4.1 RISE IN PRODUCT RECALL.

10.4.2 PATIENT COMPLIANCE REGARDING THE USE OF VACCINES AND OINTMENTS FOR TREATMENT OF GENITAL WARTS

11 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA GENITAL WARTS MARKET

11.1 IMPACT ON PRICE

11.2 IMPACT ON DEMAND

11.3 IMPACT ON SUPPLY CHAIN

11.4 STRATEGIC DECISIONS BY MANUFACTURERS

11.5 CONCLUSION

12 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY MORPHOLOGY

12.1 OVERVIEW

12.2 CAULIFLOWER-LIKE

12.3 SMOOTH PAPULAR

12.4 KERATOTIC

12.5 FLAT WARTS

13 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY TYPE

13.1 OVERVIEW

13.2 PREVENTION

13.3 DIAGNOSTIC

13.3.1 HPV TEST

13.3.2 PAP TEST

13.4 TREATMENT

13.4.1 PHARMACOLOGICAL TREATMENT

13.4.1.1 Imiquimod

13.4.1.2 Podophyllin and Podofilox

13.4.1.3 Trichloroacetic Acid

13.4.1.4 Sinecatechins

13.4.1.5 others

13.4.2 NON- PHARMACOLOGICAL TREATMENT

13.4.2.1 Cryotherapy

13.4.2.2 Electrocautery

13.4.2.3 Laser Treatment

13.4.2.4 Surgical Excision

13.4.3 GARDASIL

13.4.4 CERVARIX

14 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY CAUSE

14.1 OVERVIEW

14.2 HPV 6

14.3 HPV 11

14.4 OTHERS

15 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY LOCATION

15.1 OVERVIEW

15.2 VULVA

15.3 CERVIX UTERI

15.4 URETHRA

15.5 ANUS

15.6 SCROTUM

16 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY GENDER

16.1 OVERVIEW

16.2 FEMALE

16.3 MALE

17 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY DOSAGE

17.1 OVERVIEW

17.2 CREAM

17.3 GEL

17.4 OINTMENT

17.5 INTRAMUSCULARLY

17.6 OTHERS

18 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY END USER

18.1 OVERVIEW

18.2 HOSPITALS

18.3 DIAGNOSTIC CENTERS

18.4 SURGICAL CENTERS

18.5 AMBULATORY SURGICAL CENTERS

18.6 OTHERS

19 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL

19.1 OVERVIEW

19.2 DIRECT TENDER

19.3 PHARMACY STORES

19.4 OTHERS

20 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY REGION

20.1 MIDDLE EAST AND AFRICA

20.1.1 SOUTH AFRICA

20.1.2 SAUDI ARABIA

20.1.3 U.A.E.

20.1.4 EGYPT

20.1.5 KUWAIT

20.1.6 ISRAEL

20.1.7 REST OF MIDDLE EAST AND AFRICA

21 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: COMPANY LANDSCAPE

21.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

22 SWOT ANALYSIS

23 COMPANY PROFILE

23.1 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.

23.1.1 COMPANY SNAPSHOT

23.1.2 REVENUE ANALYSIS

23.1.3 COMPANY SHARE ANALYSIS

23.1.4 PRODUCT PORTFOLIO

23.1.5 RECENT DEVELOPMENT

23.2 GLAXOSMITHKLINE PLC

23.2.1 COMPANY SNAPSHOT

23.2.2 REVENUE ANALYSIS

23.2.3 COMPANY SHARE ANALYSIS

23.2.4 PRODUCT PORTFOLIO

23.2.5 RECENT DEVELOPMENTS

23.3 BAUSCH HEALTH COMPANIES INC.

23.3.1 COMPANY SNAPSHOT

23.3.2 REVENUE ANALYSIS

23.3.3 COMPANY SHARE ANALYSIS

23.3.4 PRODUCT PORTFOLIO

23.3.5 RECENT DEVELOPMENTS

23.4 ANI PHARMACEUTICALS, INC.

23.4.1 COMPANY SNAPSHOT

23.4.2 REVENUE ANALYSIS

23.4.3 COMPANY SHARE ANALYSIS

23.4.4 PRODUCT PORTFOLIO

23.4.5 RECENT DEVELOPMENTS

23.5 BIONTECH SE

23.5.1 COMPANY SNAPSHOT

23.5.2 REVENUE ANALYSIS

23.5.3 COMPANY SHARE ANALYSIS

23.5.4 PRODUCT PORTFOLIO

23.5.5 RECENT DEVELOPMENTS

23.6 CASSIOPEA, INC.

23.6.1 COMPANY SNAPSHOT

23.6.2 PRODUCT PORTFOLIO

23.6.3 RECENT DEVELOPMENTS

23.7 CRYOCONCEPTS LP

23.7.1 COMPANY SNAPSHOT

23.7.2 PRODUCT PORTFOLIO

23.7.3 RECENT DEVELOPMENT

23.8 CRYOIQ

23.8.1 COMPANY SNAPSHOT

23.8.2 PRODUCT PORTFOLIO

23.8.3 RECENT DEVELOPMENT

23.9 CRYOSURGERY, INC.

23.9.1 COMPANY SNAPSHOT

23.9.2 PRODUCT PORTFOLIO

23.9.3 RECENT DEVELOPMENT

23.1 EDGE PHARMA

23.10.1 COMPANY SNAPSHOT

23.10.2 PRODUCT PORTFOLIO

23.10.3 RECENT DEVELOPMENT

23.11 FOTONA

23.11.1 COMPANY SNAPSHOT

23.11.2 PRODUCT PORTFOLIO

23.11.3 RECENT DEVELOPMENTS

23.12 GLENMARK PHARMACEUTICAL INC., USA (A SUBSIDIARY OF GLENMARK PHARMACEUTICALS LTD.)

23.12.1 COMPANY SNAPSHOT

23.12.2 REVENUE ANALYSIS

23.12.3 PRODUCT PORTFOLIO

23.12.4 RECENT DEVELOPMENT

23.13 NOVAN, INC.

23.13.1 COMPANY SNAPSHOT

23.13.2 REVENUE ANALYSIS

23.13.3 PRODUCT PORTFOLIO

23.13.4 RECENT DEVELOPMENTS

23.14 ORGENESIS INC.

23.14.1 COMPANY SNAPSHOT

23.14.2 REVENUE ANALYSIS

23.14.3 PRODUCT PORTFOLIO

23.14.4 RECENT DEVELOPMENT

23.15 PERRIGO COMPANY PLC

23.15.1 COMPANY SNAPSHOT

23.15.2 REVENUE ANALYSIS

23.15.3 PRODUCT PORTFOLIO

23.15.4 RECENT DEVELOPMENT

23.16 SERUM INSTITUTE OF INDIA PVT. LTD.

23.16.1 COMPANY SNAPSHOT

23.16.2 PRODUCT PORTFOLIO

23.16.3 RECENT DEVELOPMENT

23.17 TARO PHARMACEUTICAL INDUSTRIES LTD.

23.17.1 COMPANY SNAPSHOT

23.17.2 REVENUE ANALYSIS

23.17.3 PRODUCT PORTFOLIO

23.17.4 RECENT DEVELOPMENT

23.18 VERRICA PHARMACEUTICALS

23.18.1 COMPANY SNAPSHOT

23.18.2 REVENUE ANALYSIS

23.18.3 PRODUCT PORTFOLIO

23.18.4 RECENT DEVELOPMENTS

24 QUESTIONNAIRE

25 RELATED REPORTS

List of Table

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, PIPELINE ANALYSIS

TABLE 2 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA CAULIFLOWER-LIKE IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA SMOOTH PAPULAR IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA KERATOTIC IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA FLAT WARTS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA PREVENTION IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA DIAGNOSTIC IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA DIAGNOSTIC IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA TREATMENT IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA NON- PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA HPV 6 IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA HPV 11 IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA OTHERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA VULVA IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA CERVIX UTERI IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA URETHRA IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA ANUS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA SCROTUM IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA FEMALE IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA MALE IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA CREAM IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA GEL IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA OINTMENT IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA INTRAMUSCULARLY IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA HOSPITALS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA DIAGNOSTIC CENTERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA SURGICAL CENTERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA DIRECT TENDER IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA PHARMACY STORES IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN GENITAL WARTS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA GENITAL WARTS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA GARDASIL GENITAL WARTS MARKET, BY TYPE, 2019-2028, (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA CERVARIX GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA DIAGNOSIS IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 61 SOUTH AFRICA GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 62 SOUTH AFRICA GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 SOUTH AFRICA GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 SOUTH AFRICA DIAGNOSIS IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 SOUTH AFRICA TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 SOUTH AFRICA PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 67 SOUTH AFRICA NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 68 SOUTH AFRICA GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 69 SOUTH AFRICA GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 70 SOUTH AFRICA GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 71 SOUTH AFRICA GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 72 SOUTH AFRICA GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 SOUTH AFRICA GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 SAUDI ARABIA GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 75 SAUDI ARABIA GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 SAUDI ARABIA GENITAL WARTS MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 77 SAUDI ARABIA DIAGNOSIS IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 SAUDI ARABIA TYPE IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 SAUDI ARABIA PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 SAUDI ARABIA NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 SAUDI ARABIA GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 82 SAUDI ARABIA GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 83 SAUDI ARABIA GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 84 SAUDI ARABIA GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 85 SAUDI ARABIA GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 86 SAUDI ARABIA GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 87 U.A.E. GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 88 U.A.E. GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 U.A.E. GENITAL WARTS MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 90 U.A.E. DIAGNOSIS IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 U.A.E. TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 92 U.A.E. PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 93 U.A.E. NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 94 U.A.E. GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 95 U.A.E. GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 96 U.A.E. GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 97 U.A.E. GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 98 U.A.E. GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 U.A.E. GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 100 EGYPT GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 101 EGYPT GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 102 EGYPT GENITAL WARTS MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 103 EGYPT DIAGNOSIS IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 EGYPT TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 105 EGYPT PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 106 EGYPT NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 107 EGYPT GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 108 EGYPT GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 109 EGYPT GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 110 EGYPT GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 111 EGYPT GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 112 EGYPT GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 113 KUWAIT GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 114 KUWAIT GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 115 KUWAIT GENITAL WARTS MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 116 KUWAIT DIAGNOSIS IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 117 KUWAIT TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 118 KUWAIT PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 119 KUWAIT NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 120 KUWAIT GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 121 KUWAIT GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 122 KUWAIT GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 123 KUWAIT GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 124 KUWAIT GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 125 KUWAIT GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 126 ISRAEL GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

TABLE 127 ISRAEL GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 128 ISRAEL GENITAL WARTS MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 129 ISRAEL DIAGNOSIS IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 130 ISRAEL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 131 ISRAEL PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 132 ISRAEL NON-PHARMACOLOGICAL TREATMENT IN GENITAL WARTS MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 133 ISRAEL GENITAL WARTS MARKET, BY CAUSE, 2019-2028 (USD MILLION)

TABLE 134 ISRAEL GENITAL WARTS MARKET, BY LOCATION, 2019-2028 (USD MILLION)

TABLE 135 ISRAEL GENITAL WARTS MARKET, BY GENDER, 2019-2028 (USD MILLION)

TABLE 136 ISRAEL GENITAL WARTS MARKET, BY DOSAGE, 2019-2028 (USD MILLION)

TABLE 137 ISRAEL GENITAL WARTS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 138 ISRAEL GENITAL WARTS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 139 REST OF MIDDLE EAST AND AFRICA GENITAL WARTS MARKET, BY MORPHOLOGY, 2019-2028 (USD MILLION)

 

List of Figure

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: SEGMENTATION

FIGURE 11 RISE OF MALE POPULATION IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA GENITAL WARTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 CAULIFLOWER-LIKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA GENITAL WARTS MARKET IN 2021 & 2028

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA GENITAL WARTS MARKET

FIGURE 14 PREVALENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., AUSTRALIA AND CANADA

FIGURE 15 INFECTION RATE OF SEXUALLY TRANSMITTED DISEASES (STDS) IN THE FOLLOWING COUNTRIES

FIGURE 16 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY MORPHOLOGY, 2020

FIGURE 17 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY MORPHOLOGY, 2021-2028 (USD MILLION)

FIGURE 18 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY MORPHOLOGY, CAGR (2021-2028)

FIGURE 19 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY MORPHOLOGY, LIFELINE CURVE

FIGURE 20 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY TYPE, 2020

FIGURE 21 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 22 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 23 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY CAUSE, 2020

FIGURE 25 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY CAUSE, 2021-2028 (USD MILLION)

FIGURE 26 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY CAUSE, CAGR (2021-2028)

FIGURE 27 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 28 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY LOCATION 2020

FIGURE 29 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY LOCATION 2021-2028 (USD MILLION)

FIGURE 30 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY LOCATION CAGR (2021-2028)

FIGURE 31 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY LOCATION, LIFELINE CURVE

FIGURE 32 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY GENDER 2020

FIGURE 33 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY GENDER 2021-2028 (USD MILLION)

FIGURE 34 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY GENDER CAGR (2021-2028)

FIGURE 35 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 36 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DOSAGE 2020

FIGURE 37 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DOSAGE 2021-2028 (USD MILLION)

FIGURE 38 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DOSAGE CAGR (2021-2028)

FIGURE 39 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DOSAGE, LIFELINE CURVE

FIGURE 40 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY END USER, 2020

FIGURE 41 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 42 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 43 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 45 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 46 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 47 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : SNAPSHOT (2020)

FIGURE 49 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : BY COUNTRY (2020)

FIGURE 50 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : BY COUNTRY (2021 & 2028)

FIGURE 51 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : BY COUNTRY (2020 & 2028)

FIGURE 52 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : BY MORPHOLOGY (2021-2028)

FIGURE 53 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: COMPANY SHARE 2020 (%)

 

View Infographics

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: SEGMENTATION

FIGURE 11 RISE OF MALE POPULATION IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA GENITAL WARTS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 CAULIFLOWER-LIKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA GENITAL WARTS MARKET IN 2021 & 2028

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA GENITAL WARTS MARKET

FIGURE 14 PREVALENCE OF SEXUALLY TRANSMITTED DISEASES IN THE U.S., AUSTRALIA AND CANADA

FIGURE 15 INFECTION RATE OF SEXUALLY TRANSMITTED DISEASES (STDS) IN THE FOLLOWING COUNTRIES

FIGURE 16 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY MORPHOLOGY, 2020

FIGURE 17 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY MORPHOLOGY, 2021-2028 (USD MILLION)

FIGURE 18 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY MORPHOLOGY, CAGR (2021-2028)

FIGURE 19 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY MORPHOLOGY, LIFELINE CURVE

FIGURE 20 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY TYPE, 2020

FIGURE 21 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 22 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 23 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY CAUSE, 2020

FIGURE 25 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY CAUSE, 2021-2028 (USD MILLION)

FIGURE 26 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY CAUSE, CAGR (2021-2028)

FIGURE 27 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 28 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY LOCATION 2020

FIGURE 29 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY LOCATION 2021-2028 (USD MILLION)

FIGURE 30 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY LOCATION CAGR (2021-2028)

FIGURE 31 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY LOCATION, LIFELINE CURVE

FIGURE 32 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY GENDER 2020

FIGURE 33 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY GENDER 2021-2028 (USD MILLION)

FIGURE 34 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY GENDER CAGR (2021-2028)

FIGURE 35 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 36 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DOSAGE 2020

FIGURE 37 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DOSAGE 2021-2028 (USD MILLION)

FIGURE 38 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DOSAGE CAGR (2021-2028)

FIGURE 39 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DOSAGE, LIFELINE CURVE

FIGURE 40 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY END USER, 2020

FIGURE 41 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 42 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 43 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 45 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 46 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 47 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : SNAPSHOT (2020)

FIGURE 49 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : BY COUNTRY (2020)

FIGURE 50 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : BY COUNTRY (2021 & 2028)

FIGURE 51 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : BY COUNTRY (2020 & 2028)

FIGURE 52 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET : BY MORPHOLOGY (2021-2028)

FIGURE 53 MIDDLE EAST AND AFRICA GENITAL WARTS MARKET: COMPANY SHARE 2020 (%)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19